Hermes Chan - MedMira CEO
| MIR Stock | CAD 0.09 0.01 5.56% |
CEO
Mr. Hermes Chan is the Chief Executive Officer, Director of MedMira, Inc. Prior to being appointed as President and CEO in July 2006, Mr. Chan served in a number of roles with the Corporation including President and COO, Senior Vice President, General Manager and as a research scientist with MedMira Laboratories Inc. Prior to joining MedMira Laboratories Inc., Mr. Chan served as a research scientist with Octopus Diagnostic Research, a private diagnostics company located in Wolfville, Nova Scotia. since 2013.
| Tenure | 11 years |
| Address | 155 Chain Lake Drive, Halifax, NS, Canada, B3S 1B3 |
| Phone | 902 450 1588 |
| Web | https://www.medmira.com |
MedMira Management Efficiency
The company has return on total asset (ROA) of (0.2645) % which means that it has lost $0.2645 on every $100 spent on assets. This is way below average. MedMira's management efficiency ratios could be used to measure how well MedMira manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2024. Return On Capital Employed is likely to drop to 0.13 in 2024. At this time, MedMira's Non Current Assets Total are fairly stable compared to the past year. Intangibles To Total Assets is likely to climb to 0.000001 in 2024, whereas Total Assets are likely to drop slightly above 1.7 M in 2024.Similar Executives
| Found 2 records | CEO Age | ||
| Bret Taylor | SalesforceCom CDR | 44 | |
| Eric Alexandre | Orbit Garant Drilling | N/A | |
Management Performance
| Return On Asset | -0.26 |
MedMira Leadership Team
Elected by the shareholders, the MedMira's board of directors comprises two types of representatives: MedMira inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MedMira. The board's role is to monitor MedMira's management team and ensure that shareholders' interests are well served. MedMira's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MedMira's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stewart McKelvey, Legal Counsel | ||
| Markus Meile, Chief Officer | ||
| Hermes Chan, Co-Founder, CEO and President Director, CEO of Medmira Laboratories Inc and President of Medmira Laboratories Inc | ||
| Kevin Jones, Head Marketing | ||
| Sam Ratnam, Director Affairs |
MedMira Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MedMira a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MedMira Stock Analysis
When running MedMira's price analysis, check to measure MedMira's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedMira is operating at the current time. Most of MedMira's value examination focuses on studying past and present price action to predict the probability of MedMira's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedMira's price. Additionally, you may evaluate how the addition of MedMira to your portfolios can decrease your overall portfolio volatility.